A detailed history of Royal Bank Of Canada transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 10,350 shares of YMAB stock, worth $115,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,350
Previous 3,459 199.22%
Holding current value
$115,299
Previous $41,000 229.27%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$9.95 - $15.39 $68,565 - $106,052
6,891 Added 199.22%
10,350 $135,000
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.25 $30,415 - $45,229
2,622 Added 313.26%
3,459 $41,000
Q1 2024

Nov 05, 2024

SELL
$6.57 - $18.69 $17,226 - $49,005
-2,622 Reduced 75.8%
837 $13,000
Q1 2024

May 15, 2024

SELL
$6.57 - $18.69 $62,677 - $178,302
-9,540 Reduced 91.93%
837 $13,000
Q4 2023

Feb 14, 2024

BUY
$4.88 - $7.42 $23,960 - $36,432
4,910 Added 89.81%
10,377 $70,000
Q3 2023

Nov 14, 2023

BUY
$4.86 - $7.23 $11,333 - $16,860
2,332 Added 74.39%
5,467 $29,000
Q2 2023

Aug 14, 2023

BUY
$5.68 - $10.34 $5,998 - $10,919
1,056 Added 50.79%
3,135 $21,000
Q1 2023

May 15, 2023

SELL
$2.83 - $5.11 $18,624 - $33,628
-6,581 Reduced 75.99%
2,079 $10,000
Q4 2022

Feb 14, 2023

BUY
$3.0 - $15.17 $8,532 - $43,143
2,844 Added 48.9%
8,660 $42,000
Q3 2022

Nov 14, 2022

BUY
$13.96 - $19.67 $4,146 - $5,841
297 Added 5.38%
5,816 $84,000
Q2 2022

Aug 15, 2022

SELL
$8.22 - $15.13 $32,485 - $59,793
-3,952 Reduced 41.73%
5,519 $83,000
Q1 2022

May 16, 2022

SELL
$6.55 - $17.42 $21,300 - $56,649
-3,252 Reduced 25.56%
9,471 $113,000
Q4 2021

Feb 14, 2022

SELL
$15.51 - $29.31 $44,001 - $83,152
-2,837 Reduced 18.23%
12,723 $206,000
Q3 2021

Nov 15, 2021

BUY
$27.47 - $37.31 $18,954 - $25,743
690 Added 4.64%
15,560 $444,000
Q2 2021

Aug 16, 2021

BUY
$25.45 - $37.64 $378,441 - $559,706
14,870 New
14,870 $503,000

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.